Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,025 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05708209 | The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124 | completed | — | 40 | Fayoum UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT02499120 | Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer | completed | Phase 2 | 125 | PfizerINDUSTRY | 15 | Sep 8, 2023 | clinicaltrials |
| NCT03624231 | Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC(DURTRE-RAD) | completed | Phase 2 | 18 | Ulrich KeilholzOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT03180684 | Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) | completed | Phase 2 | 33 | Inovio PharmaceuticalsINDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT04601402 | GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy | completed | Phase 1 | 11 | Genome & CompanyINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT00542308 | Zalutumumab in Non-curable Patients With SCCHN | completed | Phase 2 | 90 | GenmabINDUSTRY | 11 | Aug 3, 2023 | clinicaltrials |
| NCT03281499 | Transoral Robotic Surgery and Tailored Radiotherapy in Unknown Primary and Small Squamous Cell Head and Neck Cancer(FIND) | completed | N/A | 22 | University Health Network, TorontoOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03185013 | REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)(REVEAL 1) | completed | Phase 3 | 201 | Inovio PharmaceuticalsINDUSTRY | 19 | Jul 27, 2023 | clinicaltrials |
| NCT03575598 | Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study(SNOW) | completed | Early Phase 1 | 10 | University Health Network, TorontoOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT04554394 | CellFX System for the Treatment of Cutaneous Non-Genital Warts | completed | N/A | 62 | Pulse Biosciences, Inc.INDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT04793529 | Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study | completed | N/A | 60 | Benha UniversityOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT04949503 | A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN(Redbull-1) | completed | — | 1,931 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05120167 | Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy | completed | N/A | 288 | Cirbia Silva Campos TeixeiraOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT02207439 | Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT03215810 | Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | completed | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT04452214 | A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors | completed | Phase 1 | 19 | Cantargia ABINDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05493826 | Real World Study on the Use of Cemiplimab in Adult Patients in UK(REACT-CEMI) | completed | — | 110 | SanofiINDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05941676 | Prognostic Immune Biomarkers in HNSCC | completed | — | 55 | University Hospital OstravaOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT04572100 | Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01824901 | Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT02949700 | Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 26 | Baylor College of MedicineOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT03690921 | Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05126173 | DERM US and EU Validation Study | completed | — | 1,111 | Skin Analytics LimitedINDUSTRY | 2 | Jun 28, 2023 | clinicaltrials |
| NCT04952961 | Early Detection of Vulval CAncer Through Self-Examination (EDuCATE): Intervention Study | completed | N/A | 25 | University of ManchesterOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01935921 | Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03373760 | Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer | completed | Phase 2 | 67 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 9, 2023 | clinicaltrials |
| NCT01711541 | Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer | completed | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2023 | clinicaltrials |
| NCT02575404 | GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients | completed | Phase 1 | 36 | Providence Health & ServicesOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT00176267 | Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer | completed | Phase 2 | 26 | Susanne ArnoldOTHER | 0 | Jun 1, 2023 | clinicaltrials |
| NCT02154490 | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | completed | — | 1,864 | SWOG Cancer Research NetworkNETWORK | 2 | Jun 1, 2023 | clinicaltrials |
| NCT02766335 | Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | completed | Phase 2 / Phase 3 | 116 | SWOG Cancer Research NetworkNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT03769311 | Cetuximab in Head and Neck Cancer Patients | completed | Phase 2 | 15 | University of Wisconsin, MadisonOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT03733210 | Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer | completed | Phase 1 | 14 | Andrei IagaruOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT00176254 | Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer | completed | Phase 2 | 40 | Susanne ArnoldOTHER | 0 | May 16, 2023 | clinicaltrials |
| NCT04724096 | Evaluation of OE-MRI in Patients With H&N Cancer | completed | — | 25 | Nottingham University Hospitals NHS TrustOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05839002 | Primary Tumor Burden Score:A Novel Staging Parameter for ESCC After nCRT | completed | — | 187 | Fudan UniversityOTHER | 0 | May 3, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT05821179 | Salivary LINC00657 as a Diagnostic Biomarker for Oral Squamous Cell Carcinoma | completed | — | 36 | Fayoum UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT03758781 | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | completed | Phase 1 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT04086849 | Analysis of Patterns of Recurrence in Head and Neck Cancer Using Clinicopathomic Markers | completed | — | 450 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT03268993 | Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer | completed | N/A | 6 | University of PittsburghOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT02462187 | Topical NVN1000 for the Treatment of External Genital and Perianal Warts | completed | Phase 2 | 108 | Novan, Inc.INDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05802290 | NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN(NIVACTOR) | completed | Phase 3 | 124 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT04413214 | Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial | completed | Phase 1 | 9 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04614896 | Use of Ultrasound for Measuring Size of Oral Tongue Cancers | completed | N/A | 30 | Rigshospitalet, DenmarkOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT01515137 | Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 47 | University of PittsburghOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03888092 | Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification | completed | Phase 1 / Phase 2 | 81 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Mar 21, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Sep 13, 2023source: clinicaltrials